Last reviewed · How we verify

NCT05381779

Comparison the Effects of Inspiratory Muscle Training and Aerobic Exercise Training in Patients With Post COVID-19

Status unknown NA Last updated 25 July 2023
What this trial tests

NA trial testing Inspiratory Muscle Training Group in COVID-19 in 60 participants. Status unknown.

Timeline
5 June 2022
Primary endpoint
5 June 2024
5 August 2024

Quick facts

Lead sponsorGazi University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposesupportive care
Enrollment60
Start date5 June 2022
Primary completion5 June 2024
Estimated completion5 August 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Gazi University

Who can join

Adults 18 to 75, any sex, with COVID-19 or Aerobic Exercise. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronavirus-2019 (COVID-19) is a new virus that emerged in December 2019 and spread quickly all over the world. Problems such as hypoxia, dyspnea, increased fatigue, decreased exercise capacity and respiratory muscle strength occur in COVID-19 patients.In addition, abnormalities in skeletal muscles due to systemic inflammation, mechanical ventilation, sedation and prolonged bed rest in hospital and intensive care patients cause decreased exercise capacity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Inspiratory Muscle Training Group

Trials testing the same drug.

Other recruiting trials for COVID-19

Currently open trials in the same condition.

Other Gazi University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05381779.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing